Journal
OPEN BIOLOGY
Volume 11, Issue 1, Pages -Publisher
ROYAL SOC
DOI: 10.1098/rsob.200247
Keywords
cell lines; organoids; patient-derived xenografts; genetically engineered mouse models; cancer evolution; model systems
Categories
Funding
- Cancer Research UK (CRUK) Lung Cancer Centre of Excellence
- Roy Castle Lung Cancer Foundation
- ERC Advanced Grant (PROTEUS) [835297]
- Royal Society Napier Research Professor [RP150154]
- Francis Crick Institute
- Cancer Research UK
- UK Medical Research Council
- Wellcome Trust - Cancer Research UK
- CRUK Cancer Immunotherapy Catalyst Network
- Cancer Research UK Lung Cancer Centre of Excellence
- Rosetrees Trust
- Stoneygate Trusts
- NovoNordisk Foundation [ID16584]
- Royal Society Research Professorship Enhancement Award [RP/EA/180007]
- NIHR BRC at University College London Hospitals
- CRUK-UCL Centre, Experimental Cancer Medicine Centre
- Breast Cancer Research Foundation, (BCRF)
- Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research [SU2C-AACR-DT23-17]
- Stand Up To Cancer is a programme of the Entertainment Industry Foundation
- Scientific Partner of SU2C
- European Research Council (ERC) under the European Union [FP7-THESEUS-617844]
- European Commission ITN [607722]
- ERC
- European Research Council under the European Union [835297]
- European Union [665233]
- CRUK [A27412]
- CRUK Manchester Centre Award [A25254]
- CRUK Lung Cancer Centre of Excellence
- NIHR Manchester Biomedical Research Centre
- James Tudor Foundation
- European Research Council (ERC) [835297] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
NSCLC is the leading cause of cancer-related deaths worldwide, and although progress is being made in early detection and the development of targeted therapies and immunotherapies, the survival rate for advanced patients remains low. Effective cancer research relies on pre-clinical models that accurately reflect disease progression and patient responses to therapy.
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although advances are being made towards earlier detection and the development of impactful targeted therapies and immunotherapies, the 5-year survival of patients with advanced disease is still below 20%. Effective cancer research relies on pre-clinical model systems that accurately reflect the evolutionary course of disease progression and mimic patient responses to therapy. Here, we review pre-clinical models, including genetically engineered mouse models and patient-derived materials, such as cell lines, primary cell cultures, explant cultures and xenografts, that are currently being used to interrogate NSCLC evolution from pre-invasive disease through locally invasive cancer to the metastatic colonization of distant organ sites.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available